Sunday, June 13, 2021

How has BioLineRx (BLRX) stock been impacted by COVID-19?

BLRX trades on heavy volume after compelling Phase 3 Trials of Motixafortide (BL-8040) for the cancer treatment.


5 Stocks Under $10 That Are Poised to Take Off

Investing in stocks under $10 could significantly increase the returns on your portfolio, especially if you pick the right stocks! Within this report you will find 5 top stocks that offer investors huge upside potential and the best bang for their buck.

Add them to your watchlist before they take off!

Get the Top 5 Stocks Now!

Sponsored



BioLineRx Ltd. (BLRX), a clinical-stage biopharmaceutical firm announced today that it has obtained positive results from an interim analysis of its GENESIS Phase 3 trial of motixafortide (BL-8040) for stem cell mobilization (SCM) in multiple myeloma patients.


A Backdoor Way To Profit From Today’s Crypto Bull Market

Even if you’re not actively in crypto, you deserve to know what’s actually going on...

Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.

Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free. .

Sponsored


Multiple myeloma is cancer that forms in a type of white blood cell called a plasma cell. The cancerous plasma cells accumulate in the bone marrow and crowd out healthy blood cells.

After reporting convincing phase 3 results from the cancer treatment trials, BioLineRx stock skyrocketed 52% in the premarket today. BLRX opened the trading session at $2.28 compared to the previous close of $1.48. 

BioLineRx stock trades with a continuous bullish momentum and heavy volume as the day goes on. As we write this at 9:53 A.M EDT, BLRX was trading at $2.28 soaring by 54.05% and was leading the market with a heavy trading volume of 65 million.

The company reported that the planned interim analysis of the study’s primary endpoint was conducted independently by the Data Monitoring Committee (DMC) and the DMC has issued an immediate recommendation to BioLineRx to cease the patient enrolment after it obtained statistically significant evidence from the treatment with motixafortide.

During the planned interim analysis, it was decided that there would be 177 patients conducted into the study but after the recommendation of DMC, the company completed the enrolment at 122 patients. 

The stem cell mobilization shows a wide-scale unmet medical needs in multiple myeloma. Almost between 50% to 70% of the patients of multiple myeloma are poor mobilizers. 

The Chief Executive Officer of BioLineRx, Philip Serlin stated:

“The compelling results of this planned interim analysis are a very significant milestone for our Company, as our SCM program is the Company’s most efficient path to registration for motixafortide.”

The company will report the full results of the study after the last patient enrolled reaches 100 days of follow-up post-transplantation. BioLineRx anticipates the final results of the study in the first half of 2021.

The promising results of this cancer treatment study are one of the greatest achievements of the company. BioLineRx Ltd. (BLRX) is optimistic about the final results which will support its goal of changing the treatment pattern in autologous stem-cell mobilization. This will position motixafortide in combination with G-CSF as the new standard of care in multiple myeloma.

Latest news

 Hawaiian Holdings Inc. (HA): Weak Share Price A Buying Opportunity

Travel restrictions continue to be eased by Hawaii for tourists. Consequently, Hawaiian Airlines, owned by Hawaiian Holdings Inc. (NASDAQ: HA), stands to benefit as...

Set Your Sights On Conn’s Inc. (NASDAQ: CONN)’S Upside Potential

A furniture and home furnishings retailer, Conn's Inc. (NASDAQ: CONN), reported growth in sales in the first quarter. The company's performance surpassed analysts' predictions...

Does Investing In Roblox Corporation (RBLX) A Smart Move?

Roblox Corp. (NYSE: RBLX) released its first-quarter earnings report earlier this week. Growth in earnings and subscriber numbers are the main driving forces of...

Why is Sea Limited (SE) stock increasing rapidly?

Sea Limited (NYSE: SE), an online gaming, e-commerce, and digital payments company, reported strong earnings in the first quarter of 2021. Company revenue growth...

Related news

 Hawaiian Holdings Inc. (HA): Weak Share Price A Buying Opportunity

Travel restrictions continue to be eased by Hawaii for tourists. Consequently, Hawaiian Airlines, owned by Hawaiian Holdings Inc. (NASDAQ: HA), stands to benefit as...

Set Your Sights On Conn’s Inc. (NASDAQ: CONN)’S Upside Potential

A furniture and home furnishings retailer, Conn's Inc. (NASDAQ: CONN), reported growth in sales in the first quarter. The company's performance surpassed analysts' predictions...

Does Investing In Roblox Corporation (RBLX) A Smart Move?

Roblox Corp. (NYSE: RBLX) released its first-quarter earnings report earlier this week. Growth in earnings and subscriber numbers are the main driving forces of...

Why is Sea Limited (SE) stock increasing rapidly?

Sea Limited (NYSE: SE), an online gaming, e-commerce, and digital payments company, reported strong earnings in the first quarter of 2021. Company revenue growth...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Get Notified Of Insider Trades, Analyst Upgrades & Downgrades, Earnings Updates & Best Stocks To Trade Every Single Morning

100% free. stop anytime no spam

Get The Best Stocks To Trade Every Day!

Join now to get the Newsheater.com pre-market morning brief 100% free

We do not sell or share your information with anyone.